EMA Withdrawn: Vistide (cidofovir) — Gilead Sciences International Limited

View source ↗

Summary

Vistide (cidofovir) has been withdrawn from the European market by the marketing authorization holder Gilead Sciences International Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Retinitis

Drugs mentioned

• Vistide (cidofovir)

Snippet

Status: Withdrawn. Therapeutic area: Cytomegalovirus Retinitis. MAH: Gilead Sciences International Limited. Decision date: 22/08/2014